All In Biotech

Drug Trial Radar · NCT07930520

A Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of S247240 in Adult Male Participants With Fragile X Syndrome

A Randomized, Double-blind, Placebo-controlled, Parallel Groups, Multicenter, Phase 2 Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of S247240 Administered Orally at Different Doses in Adult Male Participants With Fragile X Syndrome

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Jan 25, 2027

Primary completion

Dec 28, 2028

Study completion Dec 28, 2028

Sponsor

Sponsor type
Industry
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, double-blind, randomized, placebo-controlled study to assess the safety and tolerability of 3 doses of S247240 in male participants with Fragile X Syndrome aged 18 to 45 years old. Participants will participate for 14 weeks of treatment. The study is also intended to characterize the PK profile of S247240 and to obtain preliminary assessments of the efficacy of S247240 in mental status examination scales and tests over the 14 weeks of treatment period.

Conditions

  • Fragile X Syndrome (FXS)

Interventions

  • S247240 Low doseDrug

    Participants will receive a liquid solution of S247240 low dose, to be taken orally twice daily.

  • S247240 Middle doseDrug

    Participants will receive a liquid solution of S247240 middle dose, to be taken orally twice daily.

  • S247240 High doseDrug

    Participants will receive a liquid solution of S247240 high dose, to be taken orally twice daily.

  • PlaceboOther

    Participants will receive a liquid solution containing no active drug, to be taken orally twice daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Adverse Events (AEs)Time frame: Through Week 16
  2. Severity of AEsTime frame: Through Week 16

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.